FDA药品溶出方法数据库
(FDA-Recommended Dissolution Methods Database)
药品通用名称 剂型 USP溶出装置 速度 溶出介质 介质体积 建议取样时间(分钟) 更新日期
Budesonide Capsule II (Paddle) with sinker 75 Acid stage: 0.1 N HCl; Buffer stage: Phosphate Buffer, pH 7.5 Acid stage: 1000; Buffer stage: 1000 Acid stage: 2 hours; Buffer stage: 0.25, 0.5, 1, 2, 4, 6 and 8 hours 2015/02/25
Budesonide Tablet (Extended Release) II (Paddle) 100 Acid Stage: 0.1 M HCl containing 0.5% Macrogol Cetostearyl Ether; Buffer Stage: pH 7.2 phosphate buffer containing 0.5% Macrogol Cetostearyl Ether. Acid Stage: 500 mL ; Buffer Stage: 1000 mL Acid Stage: 2 hours; Buffer Stage: 1, 2, 4, 6, 8 and 10 hours 2015/04/02
Bumetanide Tablet Develop a dissolution method 2024/01/03
Bupivacaine Solution (Extended Release), Infiltration II (Paddle) 50 0.025 M Sodium Phosphate Buffer with 0.03% Sodium Dodecyl Sulfate (SDS), pH 7.4 900 1, 2, 4, 8, 12, 16, 24, 36 and 48 hours 2022/07/07
Bupivacaine; Meloxicam Solution, Extended Release Develop a method to characterize in vitro release 2025/09/08
Buprenorphine Film, Transdermal (Extended Release) VI (Cylinder) with adapter, if needed 50 0.9% Sodium Chloride at 32°C 600 0.5,1, 2, 4, 6, 8,12, 16 and 24 hours 2013/05/09
Buprenorphine HCl Implant II (Paddle) 50 Water 900 1, 4, 12, 24, 36, 48, 72, 96, 120, 144 and 168 hours 2016/07/28
Buprenorphine HCl Film (Buccal) I (Basket)  100 mL round bottom vessel 100 0.05M NaH2PO4.H2O Phosphate Buffer, pH 4.5 60 10, 15, 20, 30, 45 and 60 2016/10/20
Buprenorphine HCl Tablet (Sublingual) Develop a dissolution method 2023/09/15
Buprenorphine HCl/Naloxone HCl Tablet (Sublingual) Develop a dissolution method 2023/09/15
Buprenorphine HCl/Naloxone HCl Film (Sublingual) V (Paddle over Disk) with 56 mm, 40 mesh stainless steel disk. 100 Acetate Buffer, pH 4.0 (12.5mM Sodium acetate trihydrate and 60mM glacial acetic acid. Adjust the pH with glacial acetic acid or ammonium hydroxide). 900 1, 2, 3, 5, 7 and 10 2013/10/31
Bupropion HCl Tablet (Extended Release) Develop a dissolution method 2024/01/03
Bupropion HCl Tablet Refer to FDA's Dissolution Guidance, 2018 2020/07/02
Bupropion Hydrobromide Tablet (Extended Release) I (Basket) 75 0.1 N HCl 900 1, 2, 4, 6, 8 and 10 hours 2009/06/10
Buspirone Hydrochloride Tablet Refer to FDA's Dissolution Guidance, 2018 2020/07/02
Buspirone Hydrochloride Capsule II (Paddle) 50 0.01 N HCl 500 10, 20, 30 and 45 2024/11/01
Busulfan Tablet Refer to FDA's Dissolution Guidance, 2018 2020/07/02
Busulfan Tablet Develop a dissolution method 2023/09/15
Cabergoline Tablet Refer to FDA's Dissolution Guidance, 2018 2020/07/02
Cabotegravir Suspension (Extended Release) II (Paddle) 20 0.5% w/v cetyltrimethylammonium bromide (CTAB) in 140 mM McIlvaine buffer, pH 7.4 1000 5, 10, 20, 30, 45 and 60 2023/07/07

数据库说明:

当前数据更新日期:2025年12月09日。
©2006-2025 DrugFuture->FDA-Recommended Dissolution Methods Database